Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riddle, M. C., Rydén, L., Xavier, D., Atisso, C. M., Avezum, A., Basile, J., Chung, N., Conget, I., Cushman, W. C., Franek, E., Hancu, N., Hanefeld, M., Holt, S., Jansky, P., Keltai, M., Lanas, F., Leiter, L. A., Lopez‐Jaramillo, P., Cardona‐Munoz, E. G., Pirags, V., Pogosova, N., Raubenheimer, P. J., Shaw, J., Sheu, W. H., Temelkova‐Kurktschiev, T., & , (2018). design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes, obesity & metabolism, 20(1), 42–49. http://access.bl.uk/ark:/81055/vdc_100054865381.0x000023